CD4+ responses identified in patient vaccinated with NY-ESO-1.

2004 SEP 1 - (NewsRx.com & NewsRx.net) -- Scientists have identified immunodominant CD4+ responses in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant.

According to recent research from Australia, "There is increasing evidence showing the involvement of CD4+ T cells in initiating and maintaining antitumor immune responses. NY-ESO-1 is expressed by various tumors but not normal tissues except testis. We conducted a cancer clinical trial by using full-length NY-ESO-1 protein formulated with ISCOMATRIX adjuvant and injected into patients intramuscularly. Autologous dendritic cells pulsed with NY-ESO-1 ISCOMATRIX in combination with overlapping synthetic peptides were used to identify immunodominant T cells from a vaccinated patient."

"We show here the identification and characterization of two novel CD4+ T cell epitopes," said Qiyuan Chen at Melbourne University and collaborators in Australia and the U.S. "T cells specific to these epitopes not only recognized autologous dendritic cells loaded with NY-ESO-1 but also NY-ESO-1-expressing tumor cell lines treated with IFN-gamma. One of the two responses identified was greater than the previously identified immunodominant HLA-DP4-restricted response and correlated with NY-ESO-1-specific CD8+ T cell induction after ...